• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

BioNTech (Group)

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *

 

	Start	2008-01-01 established
	Predecessor	University of Mainz (Johannes Gutenberg University)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	cancer test
	Person	Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
	Person 2	Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)
	Region	Mainz
	Country	Germany
	Street	12 An der Goldgrube
	City	55131 Mainz
	Tel	+49-6131-9084-0
		Address record changed: 2019-09-16
Basic data	Employees	D: 101 to 500 (2014-10-01)
		* Document for �About Section�: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz.
		Record changed: 2019-09-13

Advertisement

More documents for BioNTech (Group)

• [1] BioNTech SE. (10/10/19). "Press Release: BioNTech Announces Pricing of Initial Public Offering". Mainz....
• [2] BioNTech SE. (9/24/19). "Press Release: BioNTech Announces Commencement of Initial Public Offering". Mainz....
• [3] Grover, Natalie [Endpoints]. (9/10/19). "News: Hong Kong Strife Holds Up almost $100m of BioNTech's Series B Haul"....
• [4] Taylor, Nick Paul [FierceBiotech]. (9/10/19). "News: BioNTech Files for IPO after Investor Reneges on $88M Promise"....
• [5] BioNTech SE. (9/4/19). "Press Release: BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs". Mainz....
• [6] BioNTech SE. (7/9/19). "Press Release: BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline". Mainz....
• [7] BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz....
• [8] BioNTech AG. (1/23/19). "Press Release: BioNTech to Acquire Antibody Generation Unit of MAB Discovery". Mainz & Munich....
• [9] BioNTech AG. (1/4/19). "Press Release: Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors". Mainz....
• [10] BioNTech AG. (1/4/19). "Press Release: BioNTech Announces Corporate Form Transition from AG to SE; Welcomes Ryan Richardson as Senior Vice President Corporate Development and Strategy and Appoints Dr. Ulrich Wandschneider as Member of Supervisory Board"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.